US Edition12 Articles
12 Articles
According to the original report, Novo Nordisk (NVO) reported a lower than expected return on its most recent profits.This report negatively impacted the company's shares, dropping by 4% in the early hours of trading.It is not the first hit this year for the company, as its shares have recorded a decline of more than 46% to date.A significant change marked the beginning of the year for Novo Nordisk, when CEO Lars Jørgensen was replaced by Mike D…
The Creator of Ozempic Is in Terrible Trouble
While its customer are shedding pounds, Novo Nordisk, creator of the mega-hit drug Ozempic, is shedding loads of market value amid collapsing sales. One year ago, the Danish pharmaceutical giant's market cap exceeded the size of its entire home country's economy. But this week, it's continued its steady but drastic decline — which saw its CEO get the axe — by losing nearly $100 billion in value after slashing its sales forecast for the second ti…
Danish drug maker Novo Nordisk posts strong results despite competition
Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition is weighing on sales of its diabetes and obesity treatments Ozempic and Wegovy in the United States.
Sales of injectable diabetes drugs from Danish company Novo Nordisk, including Ozempic, have slowed sharply due to fierce competition and the threat of U.S. tariffs.
Coverage Details
Bias Distribution
- 40% of the sources lean Left, 40% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
